Table 3.
Treatment and clinical outcome of the patients with cardiac irAE.
| Treatment | No. (%), median (IQR) |
|---|---|
| Medicine therapy | |
| Systemic Steroids | 9 (90.0) |
| Immunoglobin | 2 (20.0) |
| AECI/ARB/ARNI | 1 (10.0) |
| β blockers | 5 (50.0) |
| Trimetazidine | 6 (60.0) |
| Coenzyme Q10 | 4 (40.0) |
| Advanced therapy | |
| Mechanical ventilation | 3 (30.0) |
| Plasma exchange | 2 (20.0) |
| Pacemaker | 1 (10.0) |
| ECMO | 0 (0.0) |
| Admission to ICU | 2 (20.0) |
| Complications | 5 (50.0) |
| Single type (myasthenia) | 1 |
| Multiple types (CCD, heart failure, respiratory failure, cardiac arrest, and myasthenia) | |
| 2a types | 2 (20.0) |
| 4b types | 1 (10.0) |
| 5c types | 1 (10.0) |
| Clinical symptoms evaluation | |
| Improvement | 8 (80.0) |
| Worse | 2 (20.0) |
| Clinical outcomes | |
| Discharge from hospital | 8 (80.0) |
| Death | 2 (20.0) |
| Hospital stay (Pts. discharge), days | 10.5 (5.75–23.0) |
| Time from diagnosis of cardiac irAE to death, days | 7.5 (5.0–10.0), N = 2 |
| Rechallenge ICIs | |
| Yes | 1 (10.0) |
| No | 7 (70.0) |
IQR, interquartile range; AECI/ARB/ARNI, angiotensin II converting enzyme inhibitors/angiotensin receptor blocker/Angiotensin receptor neprilysin inhibitor; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; CCD, cardiac conduction defect; ICIs, immune checkpoint inhibitors.
a
1 case with heart failure and myasthenia, the other case with respiratory failure, and myasthenia.
b
1 case complicated with CCD, heart failure, respiratory failure, and cardiac arrest.
c
1 case complicated with CCD, heart failure, respiratory failure, cardiac arrest, and myasthenia.